Subscribe
pills-istock-499257708-stock-colors
stock_colors / iStockphoto.com
21 February 2017Americas

DoJ sues company for selling unapproved drugs and supplements

The US Department of Justice (DoJ) has asked for an injunction to stop a Louisiana-based drug and dietary supplement manufacturer from distributing misbranded and unapproved new drugs and dietary supplements.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.

More on this story

Americas
DoJ weighs in on Amgen v Sandoz biosimilar clash
14 September 2017   The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
Ukrainians plead guilty to trafficking counterfeit drugs into the US
20 July 2020   Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.
Big Pharma
Elysium gets ChromaDex, Dartmouth vitamin patents invalidated
23 September 2021   Dietary supplements company Elysium Health has convinced a Delaware court to invalidate two vitamin B3 patents belonging to rival ChromaDex and Dartmouth College.

More features

Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case